Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cintichem was a specialized radiopharmaceutical company based in Tuxedo, New York, primarily known for operating a nuclear reactor to produce medical radioisotopes. Originally a subsidiary of Union Carbide, the company was acquired by Hoffman-La Roche in 1984 to secure a supply of isotopes like Technetium-99m and Iodine-131 for diagnostic and therapeutic use. At its peak, Cintichem was a major supplier of the world's Molybdenum-99, a precursor for the most widely used medical imaging agent. The facility was a critical component of the nuclear medicine infrastructure in the United States for several decades. However, the facility was shut down in 1990 following the discovery of radioactive leaks, leading to a comprehensive decommissioning process that concluded in the early 2000s.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cintichem.